Prednisone or Prednisolone

DRUG7 trials

Conditions

Abiraterone AcetateAndrogensAntineoplastic AgentsAntineoplastic Agents, HormonalCardiac SarcoidosisCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cytochrome P-450

Phase 1

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

TerminatedNCT05295927

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2022-03-23End: 2022-09-30Updated: 2025-02-03

Phase 2

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

CompletedNCT01972217

AstraZenecaMetastatic Castration-resistant Prostate Cancer

Start: 2014-04-01End: 2023-08-24Updated: 2023-11-14

Phase 3

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

CompletedNCT00519285

SanofiNeoplasm Metastasis, Prostatic Neoplasms

Start: 2007-08-31End: 2012-04-30Updated: 2016-07-22

Cardiac Sarcoidosis Randomized Trial

RecruitingNCT03593759

Ottawa Heart Institute Research CorporationCardiac Sarcoidosis, Sarcoidosis

Start: 2019-01-15End: 2025-12-31Target: 194Updated: 2024-12-03

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruitingNCT05288166

Eli Lilly and CompanyAbiraterone Acetate, Androgens, Antineoplastic Agents +14

Start: 2022-04-14End: 2027-10-31Updated: 2025-06-27

Unknown Phase

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

CompletedNCT01451710

Nanjing University School of MedicineIgA Nephropathy

Start: 2011-03-31End: 2012-05-31Updated: 2012-07-10

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01834209

Janssen Research & Development, LLCProstate Neoplasms

Updated: 2018-11-07

2025-09-08

PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

2025-01-145 citations

Development and validation of MOSPROC, an easily applicable predictive score of mortality for patients with prostate cancer.

Journal of Clinical Oncology2024-05-292 citations

CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2023-02-206 citations

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.

2022-09-0224 citations

A deep learning framework (DLF) to identify clinical predictors of disease progression and mortality in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel/prednisone (DP).

Journal of Clinical Oncology2022-06-01

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2022-02-1680 citations

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Cancers2021-11-2027 citations

Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).

2019-10-2080 citations

Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies.

2019-10-016 citations

PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-0114 citations

Journal of Clinical Oncology2019-03-014 citations

Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)

Annals of Oncology2018-10-011 citations

Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies.

2018-09-277 citations

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

2018-06-04294 citations

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Journal of Clinical Oncology2018-05-205 citations

Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer: Secondary analysis.

Journal of Clinical Oncology2017-02-204 citations

Olaparib combined with abiraterone in patients with metastatic prostate cancer: Safety run-in from a phase II study.

Journal of Clinical Oncology2015-05-201 citations

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

2014-12-15115 citations

Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study.

2013-06-1924 citations

1 more papers not shown